A study by Mayo Clinic has found that the prostate-specific antigen (PSA) test could be a vital tool in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer.
The study reported that men in their 40s and 50s with a baseline PSA at or above the median PSA are more likely to undergo a biopsy and be diagnosed with low-risk prostate cancer.
The PSA test measures the amount of PSA, a protein produced by cells of the prostate gland, in the patient’s blood. It allows physicians to determine a patient’s potential risk of developing prostate cancer.
High PSA levels may occur due to benign prostate enlargement or inflammation of the urinary tract.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData